The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Darier Disease — Advanced Management (Keratosis Follicularis)

Autosomal dominant genodermatosis caused by ATP2A2 (SERCA2) mutations producing impaired calcium transport, defective desmosomal adhesion, and characteristic acantholytic dyskeratosis; presents with greasy keratotic papules in seborrheic distribution, palmoplantar pits, V-shaped nail notches, mucosal involvement, and longitudinal red-white nail bands; flares with heat, sweat, sun exposure, and infection; advanced therapy includes topical and oral retinoids (acitretin, isotretinoin), photodynamic therapy, dermabrasion, and laser ablation for severe disease.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Darier Disease — Advanced Management (Keratosis Follicularis)?

Darier disease (DD), also called Darier-White disease (after Ferdinand-Jean Darier and James Clarke White who independently described it in 1889) and keratosis follicularis, is a relatively common autosomal dominant genodermatosis with prevalence approximately 1 in 30,000–55,000 (male and female equally affected), characterized by abnormal keratinization and acantholysis (loss of intercellular adhesion) producing distinctive cutaneous, nail, and mucosal manifestations.

Genetic basis: caused by loss-of-function heterozygous mutations in ATP2A2 gene (chromosome 12q23-24.1, encoding sarcoendoplasmic reticulum calcium ATPase isoform 2 [SERCA2]). SERCA2 transports calcium ions from cytosol into endoplasmic reticulum, maintaining intracellular calcium homeostasis essential for proper protein folding, trafficking, and post-translational processing. SERCA2 dysfunction impairs folding of desmosomal proteins (desmoplakin, plakoglobin, plakophilin) and their assembly into desmosomes, causing defective intercellular adhesion. ATP2A2 has >200 reported mutations including missense, nonsense, splice-site, and small insertions-deletions; mosaic mutations cause segmental Darier disease (linear, dermatomal distribution).

Clinical presentation: onset typically peripubertal (adolescence, mean age 11–15 years; range childhood to fourth decade), characterized by greasy keratotic brown-reddish-yellowish papules typically 2–4 mm in diameter, in seborrheic distribution (anterior chest, mid-back, scalp, forehead, V of neck, retroauricular area, groin, axillae, intertriginous areas). Papules may coalesce into hypertrophic, malodorous plaques. Flexural areas may develop vegetating, papillomatous lesions resembling pemphigus vegetans. Acrokeratosis verruciformis (Hopf type — small flat-topped warty papules on dorsal hands and feet, palms with pinpoint pits, plantar surface with similar pits). Characteristic nail changes occur in 92 percent: longitudinal red and white bands (linear leukonychia and erythronychia, sometimes triangular), V-shaped notches at distal free edge, subungual hyperkeratosis, splinter hemorrhages, fragility. Mucosal involvement: white papules on hard palate, gingiva, buccal mucosa, often cobblestone appearance, salivary gland calculi.

Disease flares: triggered by heat (especially humid hot weather), excessive sweating, ultraviolet (UV) exposure, mechanical friction, infections (bacterial superinfection with Staphylococcus aureus is common; herpes simplex causing Kaposi varicelliform eruption is potentially life-threatening), oral lithium, oral corticosteroids (paradoxical worsening). Lesions may worsen with menstruation, pregnancy. Disease tends to be persistent throughout life with peaks and remissions; rarely improves with age. Comorbidities: increased prevalence of neuropsychiatric disorders (depression, bipolar disorder, schizoaffective disorder, intellectual disability — possibly via SERCA2 expression in brain), epilepsy, salivary gland calculi, congenital cataracts (rare). Histopathology pathognomonic: acantholytic dyskeratosis with characteristic corps ronds (large round dyskeratotic cells in upper epidermis with perinuclear halo) and grains (smaller flattened dyskeratotic cells in granular layer), focal suprabasal acantholysis with lacunae and clefts.

Symptoms

Greasy, brown-reddish, keratotic papules in seborrheic distribution (chest, back, scalp, forehead, neck)
Coalescing hypertrophic plaques with foul body odor in flexural areas
Pinpoint pits on palms (palmar pits)
Flat-topped warty papules on dorsal hands and feet (acrokeratosis verruciformis)
Characteristic nail changes: longitudinal red-white bands, V-shaped distal notches, subungual hyperkeratosis
Cobblestone-like white papules on hard palate, gingiva, buccal mucosa
Worsening with heat, humidity, sweat, sun, infection
Adolescent onset (mean 11–15 years)
Family history of similar skin and nail changes
Severe HSV outbreaks (eczema herpeticum-like dissemination — Kaposi varicelliform eruption)
Neuropsychiatric symptoms (depression, bipolar disorder)
Salivary gland calculi (rare)

Risk Factors

Heterozygous ATP2A2 gene mutation (autosomal dominant)
Family history of Darier disease (50 percent recurrence risk)
Adolescent age of onset (peripubertal trigger)
Heat, humidity, and tropical climate exposure
Excessive sweating (hyperhidrosis)
UV exposure and sun-induced flares
Bacterial, viral (especially HSV — Kaposi varicelliform eruption risk), and fungal skin infections
Mechanical trauma and friction
Oral lithium therapy (worsens disease)
Pregnancy and hormonal fluctuations

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Greasy keratotic papules and plaques in seborrheic distribution especially with foul odor
  • Characteristic nail changes (longitudinal red-white bands, V-shaped notches)
  • Family history of Darier disease with new skin changes
  • Severe disease flare with extensive plaques and pain
  • Suspicion of HSV superinfection (Kaposi varicelliform eruption — emergent referral)
  • Disease unresponsive to topical agents — for systemic retinoid evaluation
  • Mucosal involvement and salivary gland symptoms
  • Neuropsychiatric symptoms (depression, suicidal ideation) in DD patient
  • Pregnancy planning in patient on systemic retinoids
  • Severe localized disease for surgical or laser intervention

Treatment Methods

01
Diagnostic workup: detailed personal and family history (autosomal dominant pattern, three-generation pedigree), comprehensive skin examination noting distribution and morphology, full nail examination (longitudinal red-white bands, V-notches), oral mucosa examination, palmoplantar examination (pits, acrokeratosis verruciformis), assessment for psychiatric comorbidity, skin biopsy showing pathognomonic acantholytic dyskeratosis with corps ronds and grains, ATP2A2 gene sequencing for confirmation and family counseling
02
Skin care and lifestyle: gentle skin cleansing with mild non-soap cleansers, daily emollient application (urea 10–20 percent, lactic acid 12 percent, salicylic acid 2–6 percent for keratotic areas), strict avoidance of heat-humidity-sweating (cool air conditioned environments, light cotton clothing, frequent cool showers, antiperspirants for hyperhidrosis), strict UV protection (broad-spectrum SPF 50, hat, protective clothing, mineral-based sunscreens to avoid keratolytic chemical sunscreens irritation), avoidance of irritating skincare products (alcohol-based, fragrance), wound care for fissures
03
First-line topical therapy: retinoids — adapalene 0.1–0.3 percent gel (best tolerated), tazarotene 0.05–0.1 percent gel (more potent), tretinoin 0.025–0.1 percent (often irritating); short contact application initially every other night, then nightly; topical corticosteroids (mid-potency, e.g., betamethasone valerate, mometasone) for inflamed plaques; topical antibacterials for malodorous areas (clindamycin 1 percent, mupirocin), 5-fluorouracil for refractory localized lesions
04
Systemic retinoids (cornerstone of advanced therapy): acitretin 0.5–1 mg/kg/day (most evidence; effective in 70–90 percent for clearing or substantial improvement) or isotretinoin 0.5–1 mg/kg/day; alitretinoin (in some countries); start low dose (10–25 mg/day) and titrate; expect response in 4–8 weeks; continue maintenance dose long-term as relapse occurs upon discontinuation; adverse effects: cheilitis, dry skin and mucosa, retinoid dermatitis, alopecia, photosensitivity, hyperlipidemia, hepatotoxicity, hyperostosis with chronic use, skeletal abnormalities, headache; teratogenicity (acitretin contraindicated in women planning pregnancy for 3 years post-discontinuation due to long elimination half-life of metabolite etretinate; isotretinoin requires 1 month post-discontinuation contraception); monitoring CBC, liver function, lipid profile, pregnancy test (women) before, monthly initially, then every 3 months
05
Refractory or localized severe disease: photodynamic therapy with 5-aminolevulinic acid (5-ALA) or methyl aminolevulinate (MAL) followed by light exposure (red light 630 nm) — improves keratosis and inflammation in localized disease; CO2 laser ablation, dermabrasion, surgical excision and split-thickness skin grafting for severe persistent localized plaques; cryotherapy
06
Infection management: regular skin antiseptic washes (chlorhexidine 0.5–4 percent, sodium hypochlorite bleach baths 0.005 percent — quarter cup per full bath), topical or oral antibiotics for bacterial superinfection (S. aureus most common — clindamycin, doxycycline, cephalexin); aggressive antiviral therapy at first sign of HSV infection (oral or IV acyclovir, valacyclovir, famciclovir — Kaposi varicelliform eruption is dermatologic emergency requiring hospitalization); antifungals for candidal-tinea superinfection
07
Adjunctive medical: avoidance of triggers (lithium, oral corticosteroids if possible — substitute alternatives), management of hyperhidrosis (botulinum toxin injection, glycopyrrolate, anticholinergics for severe cases), psychiatric assessment and treatment (depression, bipolar — with avoidance of lithium when possible — alternative mood stabilizers), social and psychological support (visible disease, self-esteem)
08
Emerging therapies (limited evidence): topical Janus kinase (JAK) inhibitors, low-dose naltrexone (anecdotal reports), dupilumab (anti-IL-4Rα) for some patients with prominent eczematous component, targeted topical SERCA2 modulators in research
09
Genetic counseling: autosomal dominant inheritance with 50 percent risk to offspring; preimplantation genetic diagnosis available; segmental DD (mosaic) carries lower recurrence risk than classical DD
10
Long-term: lifelong management with chronic-relapsing course; regular follow-up every 3–6 months on systemic retinoids; mental health screening; HSV-flare action plan; multidisciplinary care (dermatology, psychiatry, genetics, ENT for salivary stones); patient support groups (DEBRA, Darier Disease support communities)

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.